In mid-September, the Association wrote to the RCVS expressing concern about the August extension to the temporary guidance.
In the latest update from the RCVS, the temporary measure has now been extended to 31 October but the flowchart and guidance have been updated to add some additional steps before a POM-V product can be prescribed remotely.
The BVA says that while it supported the original decision in March as a pragmatic solution and direct response to government restrictions surrounding Covid-19, it is now questioning the ongoing need for such a relaxation in the rules.
In the letter to the RCVS, the BVA also asked for a timeframe for the publication of the results of the RCVS survey of practices’ experiences of remote consulting and prescribing. The Association's own under care working group, chaired by Nigel Gibbens, has been developing a position to respond to the RCVS review.
BVA President James Russell (pictured right) said: "We understand that allowing remote prescription of POM-Vs was a necessary measure at the height of the lockdown, as practices struggled to assess patients in person.
"However, the veterinary professions have done a fantastic job in adapting to the restrictions and are now able to work safely and see patients.
"Whilst we recognise the RCVS has provided additional guidance for the remote prescribing of POM-V, we cannot currently see any reason why a new client would be unable to access in-person veterinary care in the first instance and we are asking RCVS Council to reconsider this measure when it meets in Oct.
"It makes sense to continue allowing vets to remotely prescribe for existing patients, for example if an owner is shielding, but we feel it is no longer appropriate to be remotely prescribing to animals that have never been physically examined by the vet.
“The question of whether we should be able to remotely prescribe POM-V products without first seeing an animal is an important and live debate, and we welcome the resumption of the College’s review. But the longer that temporary measures are in place, the greater the expectation from animal owners that they will always be in place, and the harder it will be to have the discussion about the best way forward.
“As a profession, we are rightly concerned about antimicrobial resistance and we pride ourselves on the responsible use of medicines. Continually extending the temporary measures without a full analysis would risk undermining our position.”
CEVA Animal Health is giving away a digital thermometer with every purchase of three bottles of Rehydion gel Formula Plus
According to CEVA, dehydration can be a big problem for farmers, causing weakness, scouring and weight loss but Rehydion gel Formula Plus has transformed the management of this common condition. Historically treatments could not be added to milk as the bicarbonate, citrate and the high levels of glucose in the solutions inhibited milk clotting. Rehydion gel Formula Plus, however, helps to maintain a low abomasal pH and guarantees milk clotting.
The company says calves with dehydration and diarrhoea still tend to crave milk, which not only provides vital fluid but is also the best possible source of energy for weight gain. Milk also has many other advantages such as helping with gut healing and providing natural antimicrobial actions. Rehydion gel Formula Plus's high palatability and efficient dilution in milk allows weight gain to continue, even in cases of severe scour.
CEVA also has a leaflet to help farmers minimise the problem of dehydration and diarrhoea in beef and dairy cattle. To order copies and for further information contact your CEVA representative or CEVA Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG, telephone 01494 781510 or visit the website at http://www.ceva.uk.com/
Petplan has announced the finalists for the 2012 Petplan Veterinary Awards.
According to the company, the awards have been more popular than ever, with over 3,000 nominations submitted for exceptional veterinary staff across the UK.
The finalists for each of the categories are:
Vet of the YearZaila Dunbar, Queens Park Veterinary Practice - London Tony Barnes, Manor Veterinary Clinic - FolkestoneMark Taylor, Feldon Veterinary Centre - Bedworth
Vet Nurse of the YearLucy Kells, The Wildlife Aid Foundation - LeatherheadRachael Harris, Elms Veterinary Surgery - MonmouthSarah Algar, Brentknoll Veterinary Centre Ltd - Worcester
Support Staff of the YearSarah Bowler, Holly House Veterinary Surgery - KnutsfordJane Wyatt, George Hunt and Son - PoyntonCathy Campbell, Haygate Veterinary Centre - Telford
Vet Practice of the YearEastcott Veterinary Clinic and Hospital - SwindonPrince Bishop Veterinary Hospital - County DurhamBroadleys Veterinary Hospital - Stirling
Simon Masding, Petplan's Head of Sales and Partnerships, said: "The Vet of the Year Awards are the highlight of our Petplan calendar because they recognise the dedication that the veterinary industry puts into providing the nation's pets with the best possible treatment. Each year the nominations reach an even higher standard and we're delighted with this year's finalists. At Petplan we work with more veterinary professionals than any other insurance provider and it is through these awards that we thank the profession on behalf of UK pet owners."
Petplan has also announced that comedian Seann Walsh, known for his appearances on shows like Mock the Week and Michael McIntyre's Comedy Roadshow, will be this year's compère for the Vet of the Year Awards. Following in the footsteps of previous compères Michael McIntyre, Alistair McGowan, Frankie Boyle and Jason Manford; he will be entertaining this year's guests on the 12th April at Birmingham Town Hall.
For further information visit www.petplan.co.uk/vetawards/
The researchers, from the Dick Vet Equine Hospital, University of Edinburgh, Newcastle University, Istituto Zooprofilattico Sperimentale delle Venezie, and the University of Padova found that affected horses have major abnormalities in the structure of their neuromuscular junctions, microscopic sites of communication between nerves and muscles that are crucial for normal muscle function.
These abnormalities are believed to represent a toxin specific signature, effectively a ‘smoking gun’, for a neurotoxic enzyme termed a phospholipase A2.
Work is now underway to definitively identify the source of the toxin, in the hope that it will lead to novel treatments and improved diagnostics for this devastating disease.
The researchers think the toxin is likely to be produced by a microbe such as a bacterium or fungus growing on the horse’s pasture during the cold and dry weather which commonly precedes the disease.
Neurotoxic phospholipase A2 toxins are also present in the venom of many poisonous snakes, and there are many similarities between the signs of grass sickness and those of snake envenomation.
While there is no suggestion that venomous snakes cause grass sickness, it is hoped that some of the drugs that are currently being developed to treat and promote nerve regeneration in people paralysed by snake venoms can aid recovery of horses from grass sickness.
The researchers say that the neurotoxin most likely also causes the apparently identical diseases (termed animal dysautonomias) which affect cats, dogs, hares, rabbits, llamas, alpacas and sheep, and that their finding contradicts the previous leading hypothesis that grass sickness is a form of botulism.
This breakthrough is summarised in an editorial in the January 2025 issue of the Equine Veterinary Journal (EVJ).
The editorial, by Bruce McGorum and colleagues, looks at the implications of their article 'Equine grass sickness is associated with major abnormalities in the ultrastructure of skeletal neuromuscular junctions2".
Bruce said: “Identifying a probable cause of Equine Grass Sickness represents a significant breakthrough.
"We hope that this discovery will lead to novel treatments and improved diagnostics for this devastating condition.
"We are very grateful for the generous support we have received from horse owners, veterinary surgeons, scientists, charities and funding bodies.”
Bruce's editorial is currently available on Early View, free for 12 weeks, and will also be published in the January 2025 print issue of the EVJ.
Reference
Pfizer has repeated it's call for veterinary practice staff to take part in its Vet Support+ independent, industry-wide survey of employee engagement.
The survey gives practice team members, who are not partners or owners, the chance to have their say about their role and career and the future of the profession. Participants are asked to consider how they feel towards their practice and delve into issues on teamwork and communication, management techniques, personal development opportunities and working environment.
More than 3,000 vet practice staff have already completed the survey, a phenomenal early response which suggests practice employees are keen to have their voices heard. However, the closing date for the survey isn't till Friday 29th July, so if you haven't yet had a chance to do the survey, there is still time.
Pfizer Business Consultant, Vanessa Wilson, has more than 20 years experience helping businesses, teams and individuals achieve their goals. She is not surprised at the significant early response: "Questions on the level of employee engagement and satisfaction come up all the time in the work we do with practices. I'm not surprised that staff are using this opportunity to have their voice heard.
"Once completed, this survey will provide some very useful data and direction for the industry as a whole and I'd like to think it will identify opportunities for both individual career development and practice growth."
All members of staff employed within a practice who have not received a mailing and wish to participate are welcome to respond online. http://www.noesis-mi.com/surveys/employeesurvey/.
Pfizer says the findings, which are expected to be released in the autumn, will deliver a national and regional view of the current employee engagement landscape.
For further information about Vet Support+ Business Services from Pfizer visit www.vetsupportplus.co.uk.
UK veterinary surgeons strongly prefer recommending branded treatments, according to a survey conducted by specialist advertising agency Masius.
The survey, conducted amongst members of www.vetsurgeon.org, received 725 responses. It gave a conclusive insight to veterinary surgeons' opinions on branding, with 87% of respondents saying that they prefer to recommend a branded POM-V over a generic equivalent.
While branded treatments are clearly preferred over generics, vets recognise that higher prices can be an issue for clients. Price is justified mainly through a higher level of trust in the quality of the product (through extensive trialling). They also cite the added support in the event of client usage issues and the value that clients attach to brands. The cascade is a further factor, requiring the use of licensed drugs.
When it comes to supplements, vets are still in favour of brands, but less so - as the cascade is not a factor. On the issue of price differential, most vets felt that a premium of 10-25% is justifiable for a brand over a generic.
Jonathan Posner, Business Director at Masius said: "As well as the quantitative data, we also got some interesting qualitative comments as well. Looking at these, one can see a range of opinions - from the vets who value the easier client acceptance of brands, to those who feel that their professional care of the patient is paramount and that a generic should be used where it delivers the same benefit as a brand. Client ability to pay was also mentioned as a factor - a generic being more likely to lead to compliance for a client on a tight budget."
The fact that branded products come with better information and marketing support was agreed by the large majority (93%) of respondents.
All the participants in the survey were entered into a draw to win an iPad 2. The winner of the draw was Megan Wood MRCVS (pictured right) from Fife. She said: "The iPad is brilliant; I love it, and am a lucky lady!"
Muriel joined Pennard Vets as an office junior on 7th January 1950, when she was 15 years old
She earned a weekly wage of £1 10 shillings, equivalent to £1.50 in today’s money.
Andy Green, a Director at Pennard Vets, said: “Few people in this country have achieved what Muriel has.
"Pennard Vets has been around for over 125 years and Muriel’s journey with us has encompassed a staggering 70 years of that, making her one of only a handful of people in the UK who have completed 70 years with a single employer.
“Muriel is ever-present, reliable, caring, dependable and she makes the best biscuits around.
"She started work at our Sevenoaks practice as a 16-year-old in 1950, when it was just as likely a client would be bringing in a sheep, goat or horse as a dog or cat, and we used loose boxes outside for examinations, treatments isolation and even post-mortems.
“During the subsequent 70 years she was part of the growth in the practice from a single site to multiple sites.
"She was also fantastic at embracing the latest technology as the practice went from handwritten ledgers, double entry bookkeeping and dealing with the terribly difficult to decipher handwritten notes of the vets, to digitalisation, computers, online systems, email, mobile phones and a host of other technological advances.
“Throughout the years her role changed dramatically, and she learned new skills, adapted, and moved with the times, demonstrating our core values of continuous improvement, client focus, compassion and clarity every step of the way.
“When Muriel retired in 2020, sadly lockdown rules denied us the chance for a proper celebration, so we are very pleased to have been able to celebrate together with such a fabulous party.”
Muriel said: “When I started at Pennard Vets, the practice cared for large animals including horses, sheep and cattle on the local farms, but we also had some more unusual clients.
"A special highlight was fielding telephone calls from former Prime Minister, Sir Winston Churchill, who lived at Chartwell country house, near Westerham, in Kent and employed the practice to look after the health of the black swans living on the estate’s lake.
“Two of the biggest changes I saw during my seven decades at the practice were the business giving up farm work to focus on small animal work as dogs and cats became a bigger part of our families, and the transition from my handwritten notes in ledgers to modern computer systems, but I have always embraced change and enjoyed learning new skills.
"I miss everyone at Pennard Vets but will keep in touch and keep baking for them!”
Vets Now Referrals has launched a new specialist veterinary referral service to serve Aberdeen and the North.
Richard Coe MA VetMB CertSAS DipECVS MRCVS (pictured right) and Professor Stuart Carmichael BVMS MVM DSAO MRCVS will attend Ardene House Veterinary Hospital in Aberdeen on a monthly rotational basis to offer specialist care to pets from the area. Richard is a European Specialist in Small Animal Surgery and Professor Carmichael is an internationally recognised expert in veterinary orthopaedics.
By bringing these two specialist surgeons to Aberdeen, it will mean that vets can refer their clients to have their initial consultations and diagnoses locally by either Richard or Stuart, reducing the need for a lengthy journey to Vets Now Referrals in Glasgow where they are usually based. Vets Now says that where possible, treatment plans will be carried out in Aberdeen, however complex treatments may require the facilities and high tech equipment at its Glasgow Hospital.
Any vet wishing to make an enquiry about referring to Richard or Stuart should call 01224 478 041. Further information about the service can also be found on www.vetsnowreferrals.com/aberdeen.
Tricia Colville, Hospital Manager of Vets Now Referrals, Glasgow, said: "We are delighted to now be able to offer our specialist service for vets in the North of Scotland to utilise for their clients. The Vets Now Referrals Hospital in Glasgow has been so successful since it opened over a year ago, benefiting hundreds of pets and their owners. Bringing the service to Aberdeen and the surrounding region will provide vets with local access to Richard Coe and Professor Stuart Carmichael who are both renowned in their fields and for their clients this provides a convenient option which will greatly reduce time-consuming, distressing and costly journeys for them."
Ceva Animal health has launched Marbox, a broad-spectrum anti-infective, based on marbofloxacin, for the rapid treatment of bovine mastitis and respiratory disorders. According to the company, Marbox effectively provides two products in one bottle because it can be used as a high dose single injection or administered at a lower dose over several days.
Ceva says mastitis and respiratory disorders currently account for around 60% of antimicrobial prescriptions. Marbox can be used intramuscularly as a single injection for the treatment of respiratory infection. Alternatively it can be used for the treatment of acute mastitis; intravenously for the first injection and then subcutaneously at a lower dose over three days. It has a milk withdrawal of just 36 hours after subcutaneous injection.
Marbox is presented in an ergonomic CLAS vial which makes for light and shock-resistant handling, resulting in fewer breakages and reduced costs. It is available in 100 and 250 vial sizes and contains 100mg marbofloxacin per ml.
Marbox can be used in combination with Meloxidyl, Ceva's new, single shot anti-inflammatory. The product joins Ceva's bovine range of anti-infectives, which includes Cevaxel, Florkem and Spectam Injectable.
For further product information contact CEVA Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG, telephone 01494 781510 or visit the website at http://www.ceva.uk.com/
Kruuse UK has announced the launch of its new Mud Fever Kits for horses.
Kruuse says the launch follows independent studies last year by Aimi Duff BVM&S, MRCVS (Scott, Mitchell & Associates, Hexham) on the use of Manuka ND dressings for the treatment of Mud Fever.
The kit contains one complete treatment for two legs (or two complete treatments for one leg) including all dressings. There is also a step-by-step guide from the "Ask the Vet" series which explains best treatment protocol, designed to help veterinary surgeons dispense the kit directly to clients with confidence.
According to the company, the benefits of using medical grade Manuka Honey in the treatment of Mud Fever include:
Andrew Groom, Managing Director of Kruuse UK Ltd said: "We are delighted with the initial response to our unique Mud Fever Kits; such additions to our range continue to enhance the Kruuse commitment to equine wound care."
The RSPCA has published the results of a survey which found that teachers in the UK are strongly in support of teaching animal welfare in the classroom, with 93% of respondents stating they would teach animal welfare in the classroom if they had the time.
95% also said that they believe that teaching children about animal welfare would help make them more compassionate and socially aware.
According to the survey of almost 800 teachers across England and Wales, 83% felt animal welfare should be part of the national curriculum. However, some had concerns about how it would be integrated into existing frameworks, and whether it would mean more demands on already overworked teachers.
RSPCA formal education manager Claire Morris said: "We felt it is easy to sit on the sidelines and state that animal welfare should be part of the curriculum, but it is far more practical and helpful to show that it can be done."
To address these concerns, the RSPCA says it created over 90 free lesson plans for teachers, which are linked to the English and Welsh Curricula. Many of the RSPCA's lesson plans overlap in subject areas including Science, Citizenship, Literacy and Numeracy, as well as provide springboards for assemblies and student councils.
Claire added: "We urge the government to consider integrating animal welfare into our children's education as a matter of urgency - as skills such as empathy, compassion and social consciousness have value as a child goes through the education system as well as when they enter adulthood and the world of work."
The RSPCA says this is particularly important because only 70% of respondents knew what the five animal welfare needs - which are central to the Animal Welfare Act - are.
As well as looking at the ethical side of animal welfare, 92% of teachers also expressed a strong preference for lessons specifically on animals' role in food and clothing production. It was felt that with young people better connected than ever before, they have an increasing awareness of social issues and expect higher ethical standards from companies.
Bayer Animal Health has announced that its parasiticide - Advocate Spot-On Solution - is now licensed to be used weekly, and for a prolonged period of time, in severe cases of demodicosis in dogs.
According to the company, recent work carried out to obtain the new weekly indication shows a number of benefits of this increased application frequency for severely affected animals. Dogs treated on a weekly basis showed a greater reduction in mite numbers, fewer clinical signs, and improved hair regrowth and weight gain over the trial period, when compared to dogs treated monthly.
Advocate remains licensed for monthly use on mild to moderate presentations.
A spokesperson for the company said: "The new claim for the weekly use of Advocate should give veterinary surgeons a more effective route to go down when dealing with more severe cases, compared to monthly use. However, demodicosis is a complex condition which presents the practitioner with many challenges. So, from past experience with this condition, we would urge vets to be patient and also recognise the importance of treating any underlying disease process likely to exacerbate the situation."
Advocate Spot-on Solution has also been recently licensed for the prevention of Angiostrongylus vasorum, and the treatment of Crenosoma vulpis.
For further information, please contact your Bayer representative or the Bayer technical advice line on 0845 1305995.
Kruuse has launched a range of seven specialized sterile surgical disposable drapes and gowns developed for the surgery team working in equine clinics or hospitals.
The company says its new surgical sets have been designed so they include a comprehensive set of sterile drapes, towels, instrument covers and adhesive tapes needed to perform particular procedures:
Andrew Groom, Managing Director, Kruuse UK Ltd. said: "This exciting new range of products increase the Kruuse's equine product portfolio and develop further our commitment to provide specialist species available products to support the veterinary practitioner."
Scientists at the University of Liverpool have, for the first time, revealed that digital dermatitis (DD) has been present on hoof knifes used on cattle and sheep following research1 jointly funded by DairyCo and EBLEX.
The research conducted at the University investigated if DD Treponeme can be present on equipment used to trim cattle and sheep hooves. The research team, led by Dr Nicholas Evans and Professor Stuart Carter of the University of Liverpool and in collaboration with Roger Blowey MRCVS, tested trimming equipment used on cattle and sheep with digital dermatitis and after it was disinfected.
After trimming, DD was present on 97% of cattle blades and 100% of sheep blades. This was reduced to 29% and 46% respectively after disinfection.
Dr Evans said: "It has long been considered that digital dermatitis was spread in slurry which we have some evidence for and are continuing to investigate but now, for the first time, we have discovered the digital dermatitis bugs in the farm environment.
"However, the high detection rate of digital dermatitis bacteria on trimming blades soon after trimming cattle and sheep hooves from digital dermatitis cases suggests this may be a significant and worrying route for the transmission of this infectious condition."
Leigh Sullivan, who conducted the field work as part of her study, said: "Interestingly, in the world of human dentistry, a completely different species of the bacteria is found to cause gum disease. Furthermore, studies have shown it will adhere to metal on orthodontic braces which is consistent with our detection of the digital dermatitis Treponeme on metallic trimming knives."
Dr Jenny Gibbons, DairyCo research & development manager, added: "This DairyCo and EBLEX-funded study could help farmers, vets and hoof trimmers to understand more about the transmission of digital dermatitis between cows and farms. A logical precaution to limit the spread is to disinfect hoof trimming equipment between animals and between farms."
To find out more about this and other R&D projects, DairyCo is hosting a research day on 17 July at Trenault Farm, Launceston, Cornwall.
To book a place, visit: dairyco.org.uk/researchday2014
RSPCA Chief Veterinary Officer, Caroline Allen, today praised the vets and nurses who are providing essential care to animals through the crisis.
She said: “This is an incredibly challenging time for the RSPCA, trying to advise the public and keeping emergency services going with fewer staff, strained resources and in line with Government advice.
"I know this is equally stressful and challenging for vet staff too and I wanted to say a huge thank you from everyone at the RSPCA for your hard work, dedication and support you are giving the RSPCA.
"Our call centre team and officer are working hard to maintain a frontline animal welfare service, but we know there may be occasions where we are unable to attend and this may impact demand on the local vet practice."
Current guidance from the BVA defines emergency and urgent treatment as:
Caroline continued: "There are some circumstances particular to the RSPCA, such as animals that have been subject to abuse or severe neglect, or injured/unwell unowned animals, that may not initially appear to be such an “emergency” in the traditional sense, but our officers will only be collecting them if there is considered to be ‘significant impact on health/welfare and likely to deteriorate if left unmanaged’ as covered by the BVA emergency criteria. We would greatly appreciate your support in ensuring we can protect the welfare of these animals.
"Our National Control Centre will also be following the guidance from the BVA and will be limiting, wherever possible, sending members of the public to vets. However, on occasions where there is a welfare need that would justify an essential journey, we will always ask members of the public to call practices first and follow their social distancing protocols.
"For vets who provide care for our shelters and private boarders we understand the support available will be limited, we will be producing further advice for our teams around options, including remote support.
"We do understand and appreciate the current restrictions being put in place by the BVA and we do understand the very serious strain on practices and teams at this time and we hope that we can continue to work together during this unprecedented time."
Richard Casey, President of The Veterinary Marketing Group (VMG) said: “Pegasus’s survey has shown some very encouraging results. But it is also very worrying that so many of our colleagues do not feel safe from COVID19 exposure in the workplace.
"I encourage all our colleagues, regardless of whether they are management or not, to reach out to workplace colleagues. Ask them how they’re feeling, what are their concerns and what is working well?
"The same goes for clients. Let’s not assume that because we’re not yet fluent in consulting virtually that the client doesn’t value the flexibility of hearing your expert voice from the comfort of their home.
"Instead, invite feedback on how your new approaches are landing. What could be done differently? The key to managing anyone’s expectations is always clear communication. Even more so in today’s consumer driven, 24/7 economy. The veterinary practices who come out of COVID-19 well, will likely be the ones who embrace the new normal. They’ll have listened to their team and clients needs, and found ways to meet them.”
The update includes a new scoring system of low, moderate or high cancer risk which replaces the original numerical HDI scores and simplifies interpretation for clinicians, making the screening process easier to communicate with pet owners.
HT Vista says the device can now categorise cancer risk levels, based on malignant probability, with a sensitivity of 90% and a negative predictive value (NPV) of 98%.
The company says this translates to a “low cancer risk” result having a malignant probability of 10% or less, allowing veterinary teams to rule out cancer of lumps and bumps without the need for invasive procedures.
The tool can also now provide alerts for some of the low-risk cases, identifying them as lipomas, sebaceus adenomas or benign epithelial masses.
Liron Levy-Hirsch DVM MRCVS, Managing Director at HT Vista, said: "I am incredibly excited to enhance our already powerful HT Vista screening tool with a new diagnostic capability, providing veterinary teams with an even more comprehensive decision-support system.
"Our screening technology has already been a game-changer in early detection, and now, with the ability to flag specific tumour types, we are taking another significant step forward.
"This advancement empowers veterinary professionals to make even more informed decisions, supports shared decision-making with pet owners, and ultimately improves patient outcomes.
"By reducing the time from suspicion to diagnosis and treatment, we can detect cancer earlier, avoid the ‘wait and see’ approach, and help save more lives."
On the other end of the scale, a “high cancer risk” result has a malignant probability of 50% or more and indicates a stronger likelihood of malignancy.
HT Vista says these cases require additional diagnostic tests for mass identification.
The company highlights a big distinction between this and other screening modalities is that it can be nurse-led.
HT Vista will be on display and there will be live demonstrations at BSAVA Congress from the 20th to the 22nd of March 2025.
https://bit.ly/ht-vista-screening-tool
The British Safety Council has launched a new qualification to help people who drive as part of their work stay safe on the roads.
According to the organisation, the Level 2 Award in Safe Driving at Work provides work drivers with key knowledge of the hazards and risks associated with driving and equips them with valuable guidance on the measures available for reducing these risks, such as vehicle inspection, behaviour and defensive driving.
According to estimates from the Health and Safety Executive (HSE), up to a third of all road traffic accidents in Britain involve someone involved in work-related activity. In 2013, according to government figures, 1,713 people died on the road, with the total number of casualties standing at 183,670.
The Ofqual-regulated qualification, which is designed to be delivered by employers or training organisations, instructs learners on a range of topics including the particular risks associated with vulnerable road users, such as cyclists and pedestrians, the importance of regular vehicle safety checks and how to adapt driving style in response to changes in driving conditions or the actions of others.
Alex Botha, the British Safety Council's Chief Executive, said: "Driving can be a risky activity, a fact borne out by the high number of injuries and fatalities that occur annually on our roads.
"However, simple steps can be taken by employers and drivers to manage and reduce this risk. Our new Level 2 Award in Safe Driving at Work provides learners with all the essential knowledge to help them stay safe on the roads.
"Learners can expect to leave the qualification with a thorough knowledge of the main risks posed by driving - whether to themselves or other road users - and how to reduce them.
"Once registered with us, employers or training centres deliver the training using the high-quality teaching and student materials provided. Qualifications are assessed through a 45-minute multiple-choice examination that can be either taken online or on paper.
"This is a stand-alone qualification designed for delivery as a short course. It is also well-suited for integration into wider vocational programmes of study or, for example, as part of an induction programme. Students need no former knowledge or experience, so can come from a diverse range of educational and employment backgrounds.
"Safer driving habits should also feed through into workers' personal lives, providing employers with a valuable corporate social responsibility tool to help make our roads safer in and out of work."
Researchers and practitioners working in any field of academia, industry and/or clinical practice are invited to apply for an award of up to £2,000 to fund a research project relevant to the aims of the VMG, which represents veterinary professionals working in leadership and management roles.
The VMG says it has launched the scheme to help veterinary leaders embrace the challenges and opportunities faced by the sector and to help them to continue to meet patient needs effectively while remaining profitable.
VMG Junior Vice President Mr Richard Casey said: "Business landscapes are changing and the veterinary world is no exception. The VMG is ideally placed not only to support our members but also to help the wider profession. We hope that our grant scheme will support research that enhances our understanding of contemporary veterinary business, leadership and management and helps us to develop a solid evidence base for best practice. We are looking forward to receiving some exciting proposals."
Further information, including the Stage 1 application form and guidance notes, are available here: https://www.vetmg.com/vmg-research-awards/
The deadline for applications is 19 July 2019.
Environment Secretary Michael Gove said: "We are a nation of animal lovers, and the use of these punitive devices can cause harm and suffering, whether intentionally or unintentionally, to our pets.
"Organisations and MPs have campaigned against the use of shock collars passionately and we are listening to their concerns.
"We are now proposing to ban the use of electric shock collars to improve the welfare of animals."
Defra has launched a consultation on the proposals, which you can take part in here: https://consult.defra.gov.uk/animal-health-and-welfare/ban-on-electronic-training-collars-cats-and-dogs/
BVA President John Fishwick said: "We welcome the Government’s launch of a consultation on banning the use of shock collars in England and would like to see it result in an effective ban soon.
"Electronic training devices such as shock collars have been proven to cause pain and unnecessary suffering, and we know from leading veterinary behaviourists that using fear as a training tool is less effective than positive training methods, such as encouragement or rewards, and can take a toll on an animal’s overall welfare.
"We were in Westminster last week along with several animal welfare charities to highlight the issue and call upon Members of Parliament to back a ban on the use of shock collars. We were pleased to see several MPs pledge their support."
BVA will continue to push for an outright ban on the sale and import of shock collars across the UK.
Photo: Electric shock collar / Petrovskii Ian / Shuterstock
The Disciplinary Committee took the unusual step of granting an application by the respondent for anonymity, after seeing evidence of a real and immediate threat to the individual’s security if their details were made public.
For the purposes of the hearing, the respondent was therefore referred to as 'X'.
The Committee heard that the individual pleaded guilty in court in 2020 to intentionally and knowingly attempting to communicate with a person under 16 years for the purposes of sexual gratification.
Following this they were sentenced to a two-year probation order, were ordered to register on the Sexual Offences Register for five years; and were made subject to a Sexual Offences Prevention Order for five years.
At the outset of the hearing the individual admitted to all the charges against them and the Committee also noted that there was a certified copy of the conviction available.
The Committee then considered whether the conviction amounted to serious professional misconduct. In considering this, it set out the aggravating factors surrounding the case, these being that there was the risk of actual harm to a minor, that the misconduct was premeditated as the respondent had sent a number of messages via a number of online platforms over several days, that the individual displayed predatory behaviour including sending pictures and making comments of a sexual nature, and that it involved what the respondent believed to be a vulnerable individual, namely a 15-year-old child.
In mitigation, the Committee considered that there had been no actual harm caused to a human or animal in light of the fact that the 15-year-old child, who the respondent believed they were communicating with, was not real. It also took into account that the conduct related to a single isolated incident and that the individual had made open and frank admissions at an early stage.
Cerys Jones, chairing the Committee and speaking on its behalf, said: “The Committee was satisfied that the sentence imposed on X, which included X being subject to a Sexual Harm Prevention Order until 2025, resulted in the profession of veterinary nurses being brought into disrepute and, in the Committee’s judgement, public confidence in the profession would be undermined if the Committee did not find that the conviction rendered X unfit to practise as a veterinary nurse.”
In considering the individual’s sanction, the Committee heard from a character witness who said that the respondent’s actions were out of character, that they had a previously long and unblemished career, that they had made full admissions and demonstrated insight, and that they had a low risk of reoffending in the future.
Cerys said: “The Committee accepted that X had been an excellent veterinary nurse and that X’s criminal conduct did not relate to X’s practice as a veterinary nurse. However, in the Committee’s judgement, the aggravating factors outweighed the considerable mitigating factors in this case.”
She added: “The Committee decided that a suspension order was not the appropriate sanction for such a serious offence because it did not reflect the gravity of X’s conduct. In the Committee’s judgement, the wider public interest, that is the maintenance of the reputation of the profession and the College as a regulator, required a sanction of removal from the Register. The Committee considered that X had much mitigation and was clearly a dedicated veterinary nurse but the reputation of the profession was more important than the interests of X.
“Further, the Committee noted that in circumstances where X’s probation order expired in 2022, and where the ancillary orders, a Sexual Harm Prevention Order and a requirement to register on the Sexual Offences Register did not expire until 2025; the only proportionate sanction was to direct the Registrar to remove X’s name from the Register of Veterinary Nurses.”
The full findings for the case can be found at: www.rcvs.org.uk/disciplinary
Avishield IB G1-13 is indicated for active immunisation of chicks to reduce the adverse effect on cilia caused by infectious bronchitis.
The vaccine is one of two targeting the IBV 793B serotype and, with the addition of this new claim, Avishield can now be administrated on broiler, broiler breeder and laying hen farms.
Avishield IB GI-13 is a lyophilisate for oculonasal suspension/use in drinking water which contains live avian infectious bronchitis virus variant strain V-173/11: 102.7-104.6 EID50.
It has an onset of immunity 10 days after vaccination and a duration of immunity of 56 days.
Johnny Wells West, poultry key account manager at Dechra Veterinary Products, said: “The new licence extension for Avishield IB G1-13 allows greater flexibility for poultry producers to protect their flocks against infectious bronchitis on broiler, broiler breeder and laying hen farms and it is welcome news for both Dechra and the poultry industry.”
For more information contact Johnny Wells West on 07584 175758 or visit http://www.dechra.co.uk/Avishield IB G1-13
The service will be run by Dr Eloise Quince BVetMed CertAVP(SAM-F) PgCertVPS MANZCVS MRCVS and Dr Kate Allgood BVetMed CertAVP(SAM) MRCVS.
The practice says radioactive iodine therapy is the treatment of choice for hyperthyroid cats as it provides a permanent cure in up to 95% of cases.
It is administered by an iodine injection under the skin in a specialised unit by a trained vet and nurse.
The practice says a benefit of RI is that it treats ‘ectopic tissue’ that may be present outside of the thyroid gland, for example in the chest, which is not treated by surgical methods of thyroid removal.
Normal thyroid tissue is also spared, so that there is normal thyroid function post-treatment.
Though some blood tests need to be taken post-treatment, there is no need for ongoing blood samples and the monitoring of the thyroid function once successful treatment has occurred.
Elissa Norman, Clinical Director, who initially developed the idea for the iodine unit said: “The iodine unit first started as a scribble on a piece of paper and a dream of our team back in 2017 and it has taken a huge amount of dedication and effort from a large team of people to get to the point of opening in 2023.
"Radioactive iodine offers a lifetime cure for our hyperthyroid cats and we are delighted to be able to bring this service to the cats of East Anglia.”
To refer a cat patient, vets should email iodine@veterinary-hospital.co.uk.
The gallery was traditionally held in-person at the NAVC’s annual Veterinary Expo & Meeting (VMX) in Florida.
Now, for the first time since it began in 2012, the gallery is accessible to everyone everywhere months before the live event in June.
The new Virtual VMX New Product Gallery went live this week and will run until 3rd September 2021. It showcases 21 new product innovations from the following companies: BioNote; Boehringer Ingelheim Animal Health; Dechra Veterinary Products; Epicur Pharma; GVL; Hill’s Pet Nutrition, Inc.; Merck Animal Health; Neogen Corporation; Ogena Solutions; Purina; Royal Canin; Vetoquinol; Zoetis Petcare.
NAVC CEO Gene O’Neill said: "Each year, NAVC’s panel of experts select the most innovative new products and services to be showcased as part of the VMX Expo. We are excited to take this VMX staple and, for the first time, make it universally available to members of our global veterinary community everywhere.
"And they don’t have to wait until June to learn about and try these important new products. The VMX Virtual New Product Gallery launch is part of the NAVC’s expanding virtual portfolio which breaks down barriers of geography and time to make the best products the veterinary industry has to offer available to veterinary professionals worldwide.” The gallery is free to access. You can register here: https://vmxvirtual.simexpo.com/page/100
Zoetis has relaunched a broad spectrum intramammary treatment for clinical mastitis, as Lincocin Forte S.
For vets seeking to prescribe an alternative first-choice tube, independent mastitis authority Dr Andrew Bradley suggests it could be a logical, efficacious option, offering the combination of two active ingredients (lincomycin and neomycin) not available in other intramammary tubes.1
Zoetis points to studies which show that In combination, these have been found to have much higher efficacy than the sum of the two parts against Staphylococci aureus.2&3
The company says Lincocin Forte is effective against Gram positive and Gram negative pathogens, in particular staphylococcus, streptococcus and coliform bacteria.
In trials, the treatment produced clinical cure rates 21% higher than an ampicillin-cloxacillin comparison in undifferentiated mastitis cases. As first choice treatment for S uberis clinical mastitis, bacteriological cure rates were similar to a penicillin-streptomycin comparison.4 Against S aureus, aesculin-positive streptococci, and E coli, combined clinical-bacteriological cure rates were 175%, 32% and 21% higher respectively with Lincocin Forte S than ampicillin-cloxacillin treatment.
Zoetis vet Jude Roberts said these findings underpin the treatment's relaunch and its suitability as a first choice therapy for new clinical mastitis cases.
Lincocin Forte S is a water-based formulation, which Jude says helps achieve good distribution in the udder and can be easier to infuse that oil-based tubes, particularly into hardened quarters associated with E coli infections.
Dr Bradley adds that water-based formulation is likely to be less irritant to udder tissues than oil-based tubes, and may improve distribution. He also suggests that "not being a fluoroquinolone or 3rd/4th generation cephalosporin may also help vets fulfil their 'appropriate and justified' prescribing responsibilities."
The recommended treatment is one 10ml syringe per infected quarter at each of three consecutive milkings. Milk from treated cows can be sold for human consumption 84-hours after the last treatment.References: